nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABL1—Parkinson's disease	0.483	0.844	CbGaD
Dasatinib—ABCB1—Parkinson's disease	0.0893	0.156	CbGaD
Dasatinib—HCK—spinal cord—Parkinson's disease	0.000418	0.00246	CbGeAlD
Dasatinib—MAP2K5—brainstem—Parkinson's disease	0.000418	0.00246	CbGeAlD
Dasatinib—MAP3K3—cardiovascular system—Parkinson's disease	0.000418	0.00245	CbGeAlD
Dasatinib—EPHA5—central nervous system—Parkinson's disease	0.000416	0.00244	CbGeAlD
Dasatinib—ZAK—cerebellum—Parkinson's disease	0.000415	0.00244	CbGeAlD
Dasatinib—TNK2—nervous system—Parkinson's disease	0.000415	0.00244	CbGeAlD
Dasatinib—LYN—central nervous system—Parkinson's disease	0.000413	0.00243	CbGeAlD
Dasatinib—TESK1—head—Parkinson's disease	0.000411	0.00242	CbGeAlD
Dasatinib—BMPR1B—central nervous system—Parkinson's disease	0.000407	0.00239	CbGeAlD
Dasatinib—MAP3K19—central nervous system—Parkinson's disease	0.000407	0.00239	CbGeAlD
Dasatinib—EPHA5—cerebellum—Parkinson's disease	0.000406	0.00239	CbGeAlD
Dasatinib—STK36—head—Parkinson's disease	0.000405	0.00238	CbGeAlD
Dasatinib—EPHB3—head—Parkinson's disease	0.000405	0.00238	CbGeAlD
Dasatinib—KIT—embryo—Parkinson's disease	0.000404	0.00238	CbGeAlD
Dasatinib—STAT5B—brain—Parkinson's disease	0.000403	0.00237	CbGeAlD
Dasatinib—RIPK2—midbrain—Parkinson's disease	0.000403	0.00237	CbGeAlD
Dasatinib—TNK2—central nervous system—Parkinson's disease	0.000399	0.00235	CbGeAlD
Dasatinib—BMPR1B—cerebellum—Parkinson's disease	0.000398	0.00234	CbGeAlD
Dasatinib—PDGFRB—embryo—Parkinson's disease	0.000395	0.00232	CbGeAlD
Dasatinib—CSF1R—forebrain—Parkinson's disease	0.000394	0.00231	CbGeAlD
Dasatinib—RIPK2—spinal cord—Parkinson's disease	0.000393	0.00231	CbGeAlD
Dasatinib—LIMK2—head—Parkinson's disease	0.000391	0.0023	CbGeAlD
Dasatinib—TNK2—cerebellum—Parkinson's disease	0.00039	0.00229	CbGeAlD
Dasatinib—TESK1—nervous system—Parkinson's disease	0.00039	0.00229	CbGeAlD
Dasatinib—ERBB3—midbrain—Parkinson's disease	0.000386	0.00227	CbGeAlD
Dasatinib—SIK1—spinal cord—Parkinson's disease	0.000384	0.00226	CbGeAlD
Dasatinib—EPHB3—nervous system—Parkinson's disease	0.000384	0.00225	CbGeAlD
Dasatinib—STK36—nervous system—Parkinson's disease	0.000384	0.00225	CbGeAlD
Dasatinib—STK35—head—Parkinson's disease	0.000379	0.00223	CbGeAlD
Dasatinib—PDGFRA—cardiovascular system—Parkinson's disease	0.000378	0.00222	CbGeAlD
Dasatinib—CSK—head—Parkinson's disease	0.000377	0.00221	CbGeAlD
Dasatinib—ERBB3—spinal cord—Parkinson's disease	0.000377	0.00221	CbGeAlD
Dasatinib—TESK1—central nervous system—Parkinson's disease	0.000375	0.00221	CbGeAlD
Dasatinib—EPHB4—medulla oblongata—Parkinson's disease	0.000373	0.00219	CbGeAlD
Dasatinib—EPHA3—brain—Parkinson's disease	0.000373	0.00219	CbGeAlD
Dasatinib—HCK—head—Parkinson's disease	0.000372	0.00218	CbGeAlD
Dasatinib—SRC—cardiovascular system—Parkinson's disease	0.000371	0.00218	CbGeAlD
Dasatinib—LIMK2—nervous system—Parkinson's disease	0.000371	0.00218	CbGeAlD
Dasatinib—KIT—brainstem—Parkinson's disease	0.000371	0.00218	CbGeAlD
Dasatinib—JAK2—medulla oblongata—Parkinson's disease	0.00037	0.00217	CbGeAlD
Dasatinib—STK36—central nervous system—Parkinson's disease	0.000369	0.00217	CbGeAlD
Dasatinib—EPHB3—central nervous system—Parkinson's disease	0.000369	0.00217	CbGeAlD
Dasatinib—TESK1—cerebellum—Parkinson's disease	0.000367	0.00216	CbGeAlD
Dasatinib—FYN—medulla oblongata—Parkinson's disease	0.000365	0.00214	CbGeAlD
Dasatinib—SIK3—brain—Parkinson's disease	0.000363	0.00213	CbGeAlD
Dasatinib—STK36—cerebellum—Parkinson's disease	0.000361	0.00212	CbGeAlD
Dasatinib—EPHB3—cerebellum—Parkinson's disease	0.000361	0.00212	CbGeAlD
Dasatinib—STK35—nervous system—Parkinson's disease	0.00036	0.00211	CbGeAlD
Dasatinib—CSK—nervous system—Parkinson's disease	0.000357	0.0021	CbGeAlD
Dasatinib—LIMK2—central nervous system—Parkinson's disease	0.000357	0.0021	CbGeAlD
Dasatinib—MAP4K5—medulla oblongata—Parkinson's disease	0.000357	0.0021	CbGeAlD
Dasatinib—MAP3K3—medulla oblongata—Parkinson's disease	0.000357	0.0021	CbGeAlD
Dasatinib—HCK—nervous system—Parkinson's disease	0.000353	0.00207	CbGeAlD
Dasatinib—ABL1—embryo—Parkinson's disease	0.000352	0.00207	CbGeAlD
Dasatinib—MAPK14—spinal cord—Parkinson's disease	0.000351	0.00206	CbGeAlD
Dasatinib—RIPK2—head—Parkinson's disease	0.00035	0.00205	CbGeAlD
Dasatinib—LIMK2—cerebellum—Parkinson's disease	0.000349	0.00205	CbGeAlD
Dasatinib—STK35—central nervous system—Parkinson's disease	0.000346	0.00203	CbGeAlD
Dasatinib—CSK—central nervous system—Parkinson's disease	0.000344	0.00202	CbGeAlD
Dasatinib—SIK1—head—Parkinson's disease	0.000341	0.00201	CbGeAlD
Dasatinib—MAP2K5—cardiovascular system—Parkinson's disease	0.000341	0.002	CbGeAlD
Dasatinib—EPHB6—medulla oblongata—Parkinson's disease	0.000341	0.002	CbGeAlD
Dasatinib—EPHB4—midbrain—Parkinson's disease	0.000341	0.002	CbGeAlD
Dasatinib—HCK—central nervous system—Parkinson's disease	0.00034	0.00199	CbGeAlD
Dasatinib—STK35—cerebellum—Parkinson's disease	0.000338	0.00199	CbGeAlD
Dasatinib—EPHA4—head—Parkinson's disease	0.000338	0.00199	CbGeAlD
Dasatinib—ZAK—brain—Parkinson's disease	0.000337	0.00198	CbGeAlD
Dasatinib—CSK—cerebellum—Parkinson's disease	0.000336	0.00197	CbGeAlD
Dasatinib—ERBB3—head—Parkinson's disease	0.000335	0.00197	CbGeAlD
Dasatinib—FYN—midbrain—Parkinson's disease	0.000334	0.00196	CbGeAlD
Dasatinib—CSF1R—cardiovascular system—Parkinson's disease	0.000333	0.00196	CbGeAlD
Dasatinib—EPHB4—spinal cord—Parkinson's disease	0.000332	0.00195	CbGeAlD
Dasatinib—MAP3K2—head—Parkinson's disease	0.000332	0.00195	CbGeAlD
Dasatinib—JAK2—spinal cord—Parkinson's disease	0.00033	0.00194	CbGeAlD
Dasatinib—EPHA5—brain—Parkinson's disease	0.00033	0.00194	CbGeAlD
Dasatinib—ABL2—cerebellum—Parkinson's disease	0.00033	0.00194	CbGeAlD
Dasatinib—YES1—medulla oblongata—Parkinson's disease	0.00033	0.00194	CbGeAlD
Dasatinib—LYN—brain—Parkinson's disease	0.000328	0.00193	CbGeAlD
Dasatinib—MAP3K3—midbrain—Parkinson's disease	0.000326	0.00192	CbGeAlD
Dasatinib—MAP4K5—midbrain—Parkinson's disease	0.000326	0.00192	CbGeAlD
Dasatinib—FYN—spinal cord—Parkinson's disease	0.000326	0.00191	CbGeAlD
Dasatinib—SIK1—nervous system—Parkinson's disease	0.000324	0.0019	CbGeAlD
Dasatinib—BMPR1B—brain—Parkinson's disease	0.000323	0.0019	CbGeAlD
Dasatinib—MAP3K19—brain—Parkinson's disease	0.000323	0.0019	CbGeAlD
Dasatinib—ABL1—brainstem—Parkinson's disease	0.000323	0.0019	CbGeAlD
Dasatinib—BTK—brain—Parkinson's disease	0.000322	0.00189	CbGeAlD
Dasatinib—EPHA4—nervous system—Parkinson's disease	0.00032	0.00188	CbGeAlD
Dasatinib—MAP4K5—spinal cord—Parkinson's disease	0.000318	0.00187	CbGeAlD
Dasatinib—MAP3K3—spinal cord—Parkinson's disease	0.000318	0.00187	CbGeAlD
Dasatinib—ERBB3—nervous system—Parkinson's disease	0.000317	0.00186	CbGeAlD
Dasatinib—TNK2—brain—Parkinson's disease	0.000317	0.00186	CbGeAlD
Dasatinib—MAP3K2—nervous system—Parkinson's disease	0.000314	0.00185	CbGeAlD
Dasatinib—RIPK2—cerebellum—Parkinson's disease	0.000312	0.00183	CbGeAlD
Dasatinib—SIK1—central nervous system—Parkinson's disease	0.000312	0.00183	CbGeAlD
Dasatinib—MAPK14—head—Parkinson's disease	0.000312	0.00183	CbGeAlD
Dasatinib—EPHB6—midbrain—Parkinson's disease	0.000312	0.00183	CbGeAlD
Dasatinib—FGR—head—Parkinson's disease	0.00031	0.00182	CbGeAlD
Dasatinib—EPHA4—central nervous system—Parkinson's disease	0.000309	0.00181	CbGeAlD
Dasatinib—ERBB3—central nervous system—Parkinson's disease	0.000306	0.00179	CbGeAlD
Dasatinib—SIK1—cerebellum—Parkinson's disease	0.000305	0.00179	CbGeAlD
Dasatinib—EPHB6—spinal cord—Parkinson's disease	0.000304	0.00179	CbGeAlD
Dasatinib—MAP3K2—central nervous system—Parkinson's disease	0.000303	0.00178	CbGeAlD
Dasatinib—KIT—cardiovascular system—Parkinson's disease	0.000302	0.00178	CbGeAlD
Dasatinib—EPHA4—cerebellum—Parkinson's disease	0.000302	0.00177	CbGeAlD
Dasatinib—YES1—midbrain—Parkinson's disease	0.000301	0.00177	CbGeAlD
Dasatinib—FMO3—head—Parkinson's disease	0.0003	0.00176	CbGeAlD
Dasatinib—ERBB3—cerebellum—Parkinson's disease	0.000299	0.00175	CbGeAlD
Dasatinib—TESK1—brain—Parkinson's disease	0.000298	0.00175	CbGeAlD
Dasatinib—MAP3K2—cerebellum—Parkinson's disease	0.000296	0.00174	CbGeAlD
Dasatinib—MAPK14—nervous system—Parkinson's disease	0.000296	0.00174	CbGeAlD
Dasatinib—PDGFRB—cardiovascular system—Parkinson's disease	0.000295	0.00174	CbGeAlD
Dasatinib—FGR—nervous system—Parkinson's disease	0.000294	0.00173	CbGeAlD
Dasatinib—YES1—spinal cord—Parkinson's disease	0.000294	0.00173	CbGeAlD
Dasatinib—JAK2—head—Parkinson's disease	0.000293	0.00172	CbGeAlD
Dasatinib—STK36—brain—Parkinson's disease	0.000293	0.00172	CbGeAlD
Dasatinib—EPHB3—brain—Parkinson's disease	0.000293	0.00172	CbGeAlD
Dasatinib—MAP2K5—medulla oblongata—Parkinson's disease	0.000292	0.00171	CbGeAlD
Dasatinib—EPHA2—head—Parkinson's disease	0.00029	0.0017	CbGeAlD
Dasatinib—FYN—head—Parkinson's disease	0.000289	0.0017	CbGeAlD
Dasatinib—PDGFRA—spinal cord—Parkinson's disease	0.000288	0.00169	CbGeAlD
Dasatinib—CSF1R—medulla oblongata—Parkinson's disease	0.000285	0.00167	CbGeAlD
Dasatinib—MAPK14—central nervous system—Parkinson's disease	0.000285	0.00167	CbGeAlD
Dasatinib—FMO3—nervous system—Parkinson's disease	0.000284	0.00167	CbGeAlD
Dasatinib—LIMK2—brain—Parkinson's disease	0.000284	0.00167	CbGeAlD
Dasatinib—FGR—central nervous system—Parkinson's disease	0.000283	0.00166	CbGeAlD
Dasatinib—MAP4K5—head—Parkinson's disease	0.000283	0.00166	CbGeAlD
Dasatinib—MAP3K3—head—Parkinson's disease	0.000283	0.00166	CbGeAlD
Dasatinib—SRC—spinal cord—Parkinson's disease	0.000283	0.00166	CbGeAlD
Dasatinib—JAK2—nervous system—Parkinson's disease	0.000278	0.00163	CbGeAlD
Dasatinib—MAPK14—cerebellum—Parkinson's disease	0.000278	0.00163	CbGeAlD
Dasatinib—STK35—brain—Parkinson's disease	0.000275	0.00161	CbGeAlD
Dasatinib—EPHA2—nervous system—Parkinson's disease	0.000275	0.00161	CbGeAlD
Dasatinib—FYN—nervous system—Parkinson's disease	0.000274	0.00161	CbGeAlD
Dasatinib—FMO3—central nervous system—Parkinson's disease	0.000274	0.00161	CbGeAlD
Dasatinib—CSK—brain—Parkinson's disease	0.000273	0.0016	CbGeAlD
Dasatinib—EPHB6—head—Parkinson's disease	0.00027	0.00159	CbGeAlD
Dasatinib—HCK—brain—Parkinson's disease	0.00027	0.00158	CbGeAlD
Dasatinib—MAP3K3—nervous system—Parkinson's disease	0.000268	0.00157	CbGeAlD
Dasatinib—MAP4K5—nervous system—Parkinson's disease	0.000268	0.00157	CbGeAlD
Dasatinib—ABL2—brain—Parkinson's disease	0.000268	0.00157	CbGeAlD
Dasatinib—JAK2—central nervous system—Parkinson's disease	0.000268	0.00157	CbGeAlD
Dasatinib—MAP2K5—midbrain—Parkinson's disease	0.000267	0.00157	CbGeAlD
Dasatinib—EPHA2—central nervous system—Parkinson's disease	0.000265	0.00155	CbGeAlD
Dasatinib—FYN—central nervous system—Parkinson's disease	0.000264	0.00155	CbGeAlD
Dasatinib—EPHB4—cerebellum—Parkinson's disease	0.000264	0.00155	CbGeAlD
Dasatinib—ABL1—cardiovascular system—Parkinson's disease	0.000263	0.00155	CbGeAlD
Dasatinib—JAK2—cerebellum—Parkinson's disease	0.000262	0.00154	CbGeAlD
Dasatinib—YES1—head—Parkinson's disease	0.000261	0.00153	CbGeAlD
Dasatinib—CSF1R—midbrain—Parkinson's disease	0.00026	0.00153	CbGeAlD
Dasatinib—MAP2K5—spinal cord—Parkinson's disease	0.00026	0.00153	CbGeAlD
Dasatinib—KIT—medulla oblongata—Parkinson's disease	0.000258	0.00152	CbGeAlD
Dasatinib—FYN—cerebellum—Parkinson's disease	0.000258	0.00152	CbGeAlD
Dasatinib—MAP3K3—central nervous system—Parkinson's disease	0.000258	0.00152	CbGeAlD
Dasatinib—MAP4K5—central nervous system—Parkinson's disease	0.000258	0.00152	CbGeAlD
Dasatinib—EPHB6—nervous system—Parkinson's disease	0.000256	0.00151	CbGeAlD
Dasatinib—PDGFRA—head—Parkinson's disease	0.000256	0.0015	CbGeAlD
Dasatinib—CSF1R—spinal cord—Parkinson's disease	0.000254	0.00149	CbGeAlD
Dasatinib—RIPK2—brain—Parkinson's disease	0.000253	0.00149	CbGeAlD
Dasatinib—PDGFRB—medulla oblongata—Parkinson's disease	0.000252	0.00148	CbGeAlD
Dasatinib—MAP3K3—cerebellum—Parkinson's disease	0.000252	0.00148	CbGeAlD
Dasatinib—MAP4K5—cerebellum—Parkinson's disease	0.000252	0.00148	CbGeAlD
Dasatinib—SRC—head—Parkinson's disease	0.000251	0.00148	CbGeAlD
Dasatinib—YES1—nervous system—Parkinson's disease	0.000248	0.00145	CbGeAlD
Dasatinib—SIK1—brain—Parkinson's disease	0.000247	0.00145	CbGeAlD
Dasatinib—EPHB6—central nervous system—Parkinson's disease	0.000247	0.00145	CbGeAlD
Dasatinib—EPHA4—brain—Parkinson's disease	0.000245	0.00144	CbGeAlD
Dasatinib—PDGFRA—nervous system—Parkinson's disease	0.000243	0.00143	CbGeAlD
Dasatinib—ERBB3—brain—Parkinson's disease	0.000243	0.00142	CbGeAlD
Dasatinib—EPHB6—cerebellum—Parkinson's disease	0.000241	0.00142	CbGeAlD
Dasatinib—MAP3K2—brain—Parkinson's disease	0.00024	0.00141	CbGeAlD
Dasatinib—YES1—central nervous system—Parkinson's disease	0.000238	0.0014	CbGeAlD
Dasatinib—SRC—nervous system—Parkinson's disease	0.000238	0.0014	CbGeAlD
Dasatinib—KIT—midbrain—Parkinson's disease	0.000236	0.00139	CbGeAlD
Dasatinib—PDGFRA—central nervous system—Parkinson's disease	0.000234	0.00137	CbGeAlD
Dasatinib—YES1—cerebellum—Parkinson's disease	0.000233	0.00137	CbGeAlD
Dasatinib—MAP2K5—head—Parkinson's disease	0.000231	0.00136	CbGeAlD
Dasatinib—PDGFRB—midbrain—Parkinson's disease	0.000231	0.00136	CbGeAlD
Dasatinib—KIT—spinal cord—Parkinson's disease	0.00023	0.00135	CbGeAlD
Dasatinib—SRC—central nervous system—Parkinson's disease	0.000229	0.00135	CbGeAlD
Dasatinib—PDGFRA—cerebellum—Parkinson's disease	0.000229	0.00134	CbGeAlD
Dasatinib—MAPK14—brain—Parkinson's disease	0.000226	0.00133	CbGeAlD
Dasatinib—CSF1R—head—Parkinson's disease	0.000226	0.00132	CbGeAlD
Dasatinib—PDGFRB—spinal cord—Parkinson's disease	0.000225	0.00132	CbGeAlD
Dasatinib—ABL1—medulla oblongata—Parkinson's disease	0.000225	0.00132	CbGeAlD
Dasatinib—FGR—brain—Parkinson's disease	0.000225	0.00132	CbGeAlD
Dasatinib—SRC—cerebellum—Parkinson's disease	0.000224	0.00132	CbGeAlD
Dasatinib—CYP1B1—cardiovascular system—Parkinson's disease	0.000223	0.00131	CbGeAlD
Dasatinib—MAP2K5—nervous system—Parkinson's disease	0.000219	0.00129	CbGeAlD
Dasatinib—FMO3—brain—Parkinson's disease	0.000217	0.00128	CbGeAlD
Dasatinib—EPHB4—brain—Parkinson's disease	0.000214	0.00126	CbGeAlD
Dasatinib—CSF1R—nervous system—Parkinson's disease	0.000214	0.00126	CbGeAlD
Dasatinib—JAK2—brain—Parkinson's disease	0.000213	0.00125	CbGeAlD
Dasatinib—MAP2K5—central nervous system—Parkinson's disease	0.000211	0.00124	CbGeAlD
Dasatinib—EPHA2—brain—Parkinson's disease	0.00021	0.00123	CbGeAlD
Dasatinib—FYN—brain—Parkinson's disease	0.00021	0.00123	CbGeAlD
Dasatinib—MAP2K5—cerebellum—Parkinson's disease	0.000206	0.00121	CbGeAlD
Dasatinib—CSF1R—central nervous system—Parkinson's disease	0.000206	0.00121	CbGeAlD
Dasatinib—ABL1—midbrain—Parkinson's disease	0.000206	0.00121	CbGeAlD
Dasatinib—MAP3K3—brain—Parkinson's disease	0.000205	0.0012	CbGeAlD
Dasatinib—MAP4K5—brain—Parkinson's disease	0.000205	0.0012	CbGeAlD
Dasatinib—KIT—head—Parkinson's disease	0.000205	0.0012	CbGeAlD
Dasatinib—CSF1R—cerebellum—Parkinson's disease	0.000201	0.00118	CbGeAlD
Dasatinib—ABL1—spinal cord—Parkinson's disease	0.000201	0.00118	CbGeAlD
Dasatinib—PDGFRB—head—Parkinson's disease	0.0002	0.00118	CbGeAlD
Dasatinib—EPHB6—brain—Parkinson's disease	0.000196	0.00115	CbGeAlD
Dasatinib—KIT—nervous system—Parkinson's disease	0.000194	0.00114	CbGeAlD
Dasatinib—PDGFRB—nervous system—Parkinson's disease	0.00019	0.00111	CbGeAlD
Dasatinib—YES1—brain—Parkinson's disease	0.000189	0.00111	CbGeAlD
Dasatinib—KIT—central nervous system—Parkinson's disease	0.000187	0.0011	CbGeAlD
Dasatinib—PDGFRA—brain—Parkinson's disease	0.000186	0.00109	CbGeAlD
Dasatinib—KIT—cerebellum—Parkinson's disease	0.000183	0.00107	CbGeAlD
Dasatinib—PDGFRB—central nervous system—Parkinson's disease	0.000183	0.00107	CbGeAlD
Dasatinib—SRC—brain—Parkinson's disease	0.000182	0.00107	CbGeAlD
Dasatinib—PDGFRB—cerebellum—Parkinson's disease	0.000178	0.00105	CbGeAlD
Dasatinib—ABL1—head—Parkinson's disease	0.000178	0.00105	CbGeAlD
Dasatinib—ABL1—nervous system—Parkinson's disease	0.000169	0.000993	CbGeAlD
Dasatinib—MAP2K5—brain—Parkinson's disease	0.000167	0.000984	CbGeAlD
Dasatinib—CSF1R—brain—Parkinson's disease	0.000163	0.00096	CbGeAlD
Dasatinib—ABL1—central nervous system—Parkinson's disease	0.000163	0.000956	CbGeAlD
Dasatinib—ABL1—cerebellum—Parkinson's disease	0.000159	0.000934	CbGeAlD
Dasatinib—CYP1B1—head—Parkinson's disease	0.000151	0.000887	CbGeAlD
Dasatinib—KIT—brain—Parkinson's disease	0.000148	0.000872	CbGeAlD
Dasatinib—PDGFRB—brain—Parkinson's disease	0.000145	0.000852	CbGeAlD
Dasatinib—CYP1B1—nervous system—Parkinson's disease	0.000143	0.000841	CbGeAlD
Dasatinib—ABCG2—medulla oblongata—Parkinson's disease	0.000142	0.000833	CbGeAlD
Dasatinib—CYP1B1—central nervous system—Parkinson's disease	0.000138	0.00081	CbGeAlD
Dasatinib—CYP1B1—cerebellum—Parkinson's disease	0.000135	0.000791	CbGeAlD
Dasatinib—ABCG2—midbrain—Parkinson's disease	0.00013	0.000762	CbGeAlD
Dasatinib—ABL1—brain—Parkinson's disease	0.000129	0.000759	CbGeAlD
Dasatinib—ABCG2—spinal cord—Parkinson's disease	0.000127	0.000743	CbGeAlD
Dasatinib—ABCB1—embryo—Parkinson's disease	0.000109	0.000643	CbGeAlD
Dasatinib—CYP1B1—brain—Parkinson's disease	0.000109	0.000643	CbGeAlD
Dasatinib—CYP1A1—head—Parkinson's disease	0.000107	0.000627	CbGeAlD
Dasatinib—CYP1A1—nervous system—Parkinson's disease	0.000101	0.000594	CbGeAlD
Dasatinib—ABCG2—cerebellum—Parkinson's disease	0.0001	0.000589	CbGeAlD
Dasatinib—CYP1A1—central nervous system—Parkinson's disease	9.74e-05	0.000572	CbGeAlD
Dasatinib—ABCB1—forebrain—Parkinson's disease	9.68e-05	0.000569	CbGeAlD
Dasatinib—ABCB1—cardiovascular system—Parkinson's disease	8.19e-05	0.000481	CbGeAlD
Dasatinib—ABCG2—brain—Parkinson's disease	8.15e-05	0.000479	CbGeAlD
Dasatinib—CYP1A1—brain—Parkinson's disease	7.73e-05	0.000454	CbGeAlD
Dasatinib—CYP3A4—nervous system—Parkinson's disease	7.43e-05	0.000436	CbGeAlD
Dasatinib—CYP3A4—central nervous system—Parkinson's disease	7.15e-05	0.00042	CbGeAlD
Dasatinib—ABCB1—medulla oblongata—Parkinson's disease	7e-05	0.000411	CbGeAlD
Dasatinib—ABCB1—midbrain—Parkinson's disease	6.39e-05	0.000376	CbGeAlD
Dasatinib—ABCB1—spinal cord—Parkinson's disease	6.24e-05	0.000366	CbGeAlD
Dasatinib—ABCB1—head—Parkinson's disease	5.54e-05	0.000326	CbGeAlD
Dasatinib—ABCB1—nervous system—Parkinson's disease	5.26e-05	0.000309	CbGeAlD
Dasatinib—ABCB1—central nervous system—Parkinson's disease	5.06e-05	0.000297	CbGeAlD
Dasatinib—ABCB1—cerebellum—Parkinson's disease	4.95e-05	0.000291	CbGeAlD
Dasatinib—ABCB1—brain—Parkinson's disease	4.02e-05	0.000236	CbGeAlD
Dasatinib—LCK—Disease—APOE—Parkinson's disease	3.95e-06	1.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EDN1—Parkinson's disease	3.93e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IGF1R—Parkinson's disease	3.93e-06	1.53e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—IL6—Parkinson's disease	3.91e-06	1.52e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GSTM1—Parkinson's disease	3.89e-06	1.51e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NGF—Parkinson's disease	3.89e-06	1.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EDN1—Parkinson's disease	3.88e-06	1.51e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ADRBK1—Parkinson's disease	3.88e-06	1.51e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—DDC—Parkinson's disease	3.88e-06	1.51e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—INS—Parkinson's disease	3.87e-06	1.5e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—INS—Parkinson's disease	3.85e-06	1.5e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—IL6—Parkinson's disease	3.85e-06	1.5e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—APOE—Parkinson's disease	3.82e-06	1.49e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NGF—Parkinson's disease	3.81e-06	1.48e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CYP2D6—Parkinson's disease	3.8e-06	1.48e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—MAPK8—Parkinson's disease	3.8e-06	1.48e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—IL6—Parkinson's disease	3.79e-06	1.47e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—IL6—Parkinson's disease	3.79e-06	1.47e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—MTHFR—Parkinson's disease	3.78e-06	1.47e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL1B—Parkinson's disease	3.77e-06	1.46e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—IL6—Parkinson's disease	3.77e-06	1.46e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—DRD2—Parkinson's disease	3.76e-06	1.46e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HTR7—Parkinson's disease	3.76e-06	1.46e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MTHFR—Parkinson's disease	3.75e-06	1.46e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NGF—Parkinson's disease	3.75e-06	1.46e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CTGF—Parkinson's disease	3.73e-06	1.45e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GPX1—Parkinson's disease	3.73e-06	1.45e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—IL6—Parkinson's disease	3.73e-06	1.45e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CASP3—Parkinson's disease	3.72e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HTR2A—Parkinson's disease	3.71e-06	1.44e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	3.68e-06	1.43e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTA4—Parkinson's disease	3.66e-06	1.42e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—MAPK8—Parkinson's disease	3.65e-06	1.42e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NQO1—Parkinson's disease	3.64e-06	1.41e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HTR2A—Parkinson's disease	3.63e-06	1.41e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	3.61e-06	1.4e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NGF—Parkinson's disease	3.61e-06	1.4e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—Parkinson's disease	3.59e-06	1.39e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—TH—Parkinson's disease	3.59e-06	1.39e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—Parkinson's disease	3.58e-06	1.39e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HTR2A—Parkinson's disease	3.57e-06	1.39e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NGF—Parkinson's disease	3.57e-06	1.39e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF2—Parkinson's disease	3.56e-06	1.38e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—Parkinson's disease	3.54e-06	1.38e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—APOE—Parkinson's disease	3.52e-06	1.37e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—APOE—Parkinson's disease	3.5e-06	1.36e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CYP2E1—Parkinson's disease	3.48e-06	1.35e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—MAPK8—Parkinson's disease	3.46e-06	1.34e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—INS—Parkinson's disease	3.45e-06	1.34e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—APOE—Parkinson's disease	3.45e-06	1.34e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYCS—Parkinson's disease	3.44e-06	1.34e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—MTHFR—Parkinson's disease	3.44e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1R—Parkinson's disease	3.44e-06	1.34e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HTR2A—Parkinson's disease	3.44e-06	1.34e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NQO1—Parkinson's disease	3.44e-06	1.34e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MAPK8—Parkinson's disease	3.42e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—Parkinson's disease	3.42e-06	1.33e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—Parkinson's disease	3.4e-06	1.32e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CASP3—Parkinson's disease	3.4e-06	1.32e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EDN1—Parkinson's disease	3.4e-06	1.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL1B—Parkinson's disease	3.4e-06	1.32e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HTR2A—Parkinson's disease	3.4e-06	1.32e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—TH—Parkinson's disease	3.39e-06	1.32e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—Parkinson's disease	3.38e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—APOE—Parkinson's disease	3.37e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—INS—Parkinson's disease	3.37e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—Parkinson's disease	3.34e-06	1.3e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—Parkinson's disease	3.33e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL1B—Parkinson's disease	3.33e-06	1.29e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—APOE—Parkinson's disease	3.32e-06	1.29e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL1B—Parkinson's disease	3.31e-06	1.29e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—Parkinson's disease	3.31e-06	1.29e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	3.3e-06	1.28e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—Parkinson's disease	3.29e-06	1.28e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CASP3—Parkinson's disease	3.28e-06	1.27e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL1B—Parkinson's disease	3.27e-06	1.27e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—INS—Parkinson's disease	3.27e-06	1.27e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MAOB—Parkinson's disease	3.26e-06	1.27e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CYCS—Parkinson's disease	3.25e-06	1.26e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—Parkinson's disease	3.25e-06	1.26e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—Parkinson's disease	3.24e-06	1.26e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—APOE—Parkinson's disease	3.2e-06	1.24e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—APOE—Parkinson's disease	3.2e-06	1.24e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—Parkinson's disease	3.17e-06	1.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—APOE—Parkinson's disease	3.16e-06	1.23e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL1B—Parkinson's disease	3.15e-06	1.22e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF2—Parkinson's disease	3.15e-06	1.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—Parkinson's disease	3.13e-06	1.22e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MAPK8—Parkinson's disease	3.13e-06	1.21e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NGF—Parkinson's disease	3.12e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—MAPK8—Parkinson's disease	3.12e-06	1.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL1B—Parkinson's disease	3.11e-06	1.21e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	3.1e-06	1.21e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—COMT—Parkinson's disease	3.05e-06	1.18e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—MAPK8—Parkinson's disease	3.05e-06	1.18e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1R—Parkinson's disease	3.05e-06	1.18e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	3.04e-06	1.18e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—MAPK8—Parkinson's disease	3.04e-06	1.18e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GSTP1—Parkinson's disease	3.04e-06	1.18e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MAOA—Parkinson's disease	3.03e-06	1.18e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—Parkinson's disease	3.02e-06	1.17e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MAPK8—Parkinson's disease	3.01e-06	1.17e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EDN1—Parkinson's disease	3.01e-06	1.17e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—INS—Parkinson's disease	3.01e-06	1.17e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—MAPK8—Parkinson's disease	3e-06	1.17e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—HMOX1—Parkinson's disease	2.99e-06	1.16e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—DDC—Parkinson's disease	2.99e-06	1.16e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—INS—Parkinson's disease	2.99e-06	1.16e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CTGF—Parkinson's disease	2.98e-06	1.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—Parkinson's disease	2.98e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HTR2A—Parkinson's disease	2.97e-06	1.16e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—INS—Parkinson's disease	2.94e-06	1.14e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—Parkinson's disease	2.92e-06	1.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—MAPK8—Parkinson's disease	2.89e-06	1.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—INS—Parkinson's disease	2.88e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—COMT—Parkinson's disease	2.88e-06	1.12e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CASP3—Parkinson's disease	2.88e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ABCB1—Parkinson's disease	2.87e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GSTP1—Parkinson's disease	2.87e-06	1.11e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MAOA—Parkinson's disease	2.86e-06	1.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—MAPK8—Parkinson's disease	2.85e-06	1.11e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—INS—Parkinson's disease	2.84e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—HMOX1—Parkinson's disease	2.83e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	2.82e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GSTM1—Parkinson's disease	2.79e-06	1.08e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	2.78e-06	1.08e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NGF—Parkinson's disease	2.77e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—APOE—Parkinson's disease	2.77e-06	1.07e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—Parkinson's disease	2.75e-06	1.07e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—Parkinson's disease	2.75e-06	1.07e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NQO1—Parkinson's disease	2.75e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—Parkinson's disease	2.74e-06	1.06e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—INS—Parkinson's disease	2.74e-06	1.06e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—INS—Parkinson's disease	2.73e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL1B—Parkinson's disease	2.73e-06	1.06e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ABCB1—Parkinson's disease	2.72e-06	1.05e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TH—Parkinson's disease	2.71e-06	1.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—INS—Parkinson's disease	2.7e-06	1.05e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GPX1—Parkinson's disease	2.67e-06	1.04e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MAPK8—Parkinson's disease	2.64e-06	1.03e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GSTM1—Parkinson's disease	2.64e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HTR2A—Parkinson's disease	2.63e-06	1.02e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—Parkinson's disease	2.61e-06	1.01e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYCS—Parkinson's disease	2.6e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CASP3—Parkinson's disease	2.57e-06	9.98e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	2.54e-06	9.88e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GPX1—Parkinson's disease	2.52e-06	9.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MAOB—Parkinson's disease	2.52e-06	9.78e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—MAPK8—Parkinson's disease	2.5e-06	9.71e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MTHFR—Parkinson's disease	2.47e-06	9.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—APOE—Parkinson's disease	2.45e-06	9.51e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CASP3—Parkinson's disease	2.43e-06	9.45e-06	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—Parkinson's disease	2.43e-06	9.43e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	2.42e-06	9.42e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL1B—Parkinson's disease	2.41e-06	9.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CTGF—Parkinson's disease	2.38e-06	9.24e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—INS—Parkinson's disease	2.36e-06	9.18e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK8—Parkinson's disease	2.36e-06	9.17e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—Parkinson's disease	2.33e-06	9.06e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—Parkinson's disease	2.33e-06	9.05e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—COMT—Parkinson's disease	2.3e-06	8.94e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—APOE—Parkinson's disease	2.3e-06	8.92e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTP1—Parkinson's disease	2.29e-06	8.9e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MAOA—Parkinson's disease	2.29e-06	8.88e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HMOX1—Parkinson's disease	2.26e-06	8.78e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK8—Parkinson's disease	2.24e-06	8.68e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	2.22e-06	8.61e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK8—Parkinson's disease	2.21e-06	8.6e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—Parkinson's disease	2.21e-06	8.58e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NQO1—Parkinson's disease	2.19e-06	8.52e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CASP3—Parkinson's disease	2.19e-06	8.51e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—Parkinson's disease	2.18e-06	8.48e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOE—Parkinson's disease	2.17e-06	8.42e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TH—Parkinson's disease	2.16e-06	8.39e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—Parkinson's disease	2.15e-06	8.37e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—Parkinson's disease	2.15e-06	8.33e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—Parkinson's disease	2.11e-06	8.21e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—Parkinson's disease	2.11e-06	8.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—INS—Parkinson's disease	2.09e-06	8.12e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYCS—Parkinson's disease	2.07e-06	8.06e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—Parkinson's disease	2.04e-06	7.92e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—Parkinson's disease	2.03e-06	7.9e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—Parkinson's disease	2.02e-06	7.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK8—Parkinson's disease	2.01e-06	7.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—Parkinson's disease	2.01e-06	7.8e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—Parkinson's disease	2e-06	7.75e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—Parkinson's disease	2e-06	7.75e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—Parkinson's disease	1.99e-06	7.73e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK8—Parkinson's disease	1.97e-06	7.66e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—INS—Parkinson's disease	1.96e-06	7.62e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—Parkinson's disease	1.95e-06	7.57e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK8—Parkinson's disease	1.94e-06	7.54e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—Parkinson's disease	1.94e-06	7.53e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—Parkinson's disease	1.92e-06	7.47e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—Parkinson's disease	1.92e-06	7.45e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.87e-06	7.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK8—Parkinson's disease	1.87e-06	7.26e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.86e-06	7.23e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—INS—Parkinson's disease	1.85e-06	7.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—Parkinson's disease	1.85e-06	7.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK8—Parkinson's disease	1.85e-06	7.17e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—COMT—Parkinson's disease	1.84e-06	7.14e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—Parkinson's disease	1.84e-06	7.13e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.84e-06	7.13e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—Parkinson's disease	1.83e-06	7.1e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MAOA—Parkinson's disease	1.82e-06	7.09e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—Parkinson's disease	1.82e-06	7.08e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—Parkinson's disease	1.8e-06	7.01e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—Parkinson's disease	1.77e-06	6.88e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—Parkinson's disease	1.76e-06	6.83e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOE—Parkinson's disease	1.73e-06	6.73e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—Parkinson's disease	1.73e-06	6.72e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.71e-06	6.65e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.69e-06	6.57e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—Parkinson's disease	1.69e-06	6.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—Parkinson's disease	1.68e-06	6.54e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—Parkinson's disease	1.68e-06	6.53e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TH—Parkinson's disease	1.67e-06	6.48e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK8—Parkinson's disease	1.62e-06	6.28e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—Parkinson's disease	1.61e-06	6.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.6e-06	6.22e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—Parkinson's disease	1.6e-06	6.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—Parkinson's disease	1.56e-06	6.05e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—Parkinson's disease	1.51e-06	5.86e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—Parkinson's disease	1.49e-06	5.77e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—INS—Parkinson's disease	1.48e-06	5.75e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—Parkinson's disease	1.47e-06	5.73e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK8—Parkinson's disease	1.43e-06	5.56e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—Parkinson's disease	1.43e-06	5.55e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—COMT—Parkinson's disease	1.42e-06	5.51e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—Parkinson's disease	1.41e-06	5.49e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	1.41e-06	5.48e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MAOA—Parkinson's disease	1.41e-06	5.47e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	1.39e-06	5.41e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOE—Parkinson's disease	1.38e-06	5.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	1.34e-06	5.19e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—Parkinson's disease	1.3e-06	5.07e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	1.3e-06	5.04e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—Parkinson's disease	1.29e-06	5e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—Parkinson's disease	1.26e-06	4.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—Parkinson's disease	1.24e-06	4.82e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—Parkinson's disease	1.24e-06	4.82e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—Parkinson's disease	1.19e-06	4.64e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—INS—Parkinson's disease	1.18e-06	4.59e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—Parkinson's disease	1.18e-06	4.58e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	1.15e-06	4.45e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOE—Parkinson's disease	1.07e-06	4.14e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—Parkinson's disease	1.03e-06	4.01e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—Parkinson's disease	9.14e-07	3.55e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—INS—Parkinson's disease	9.12e-07	3.54e-06	CbGpPWpGaD
